Syndax Announces Participation at Two Upcoming Investor Conferences
- A virtual fireside chat at the TD Cowen 4th Annual Oncology Innovation Summit at
2:30 p.m. ETon Wednesday, May 31, 2023.
- A fireside chat at the Goldman Sachs Annual Global Healthcare Conference at
1:40 p.m. ET/ 10:40 a.m. PTon Monday, June 12, 2023in Dana Point, CA.
A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal clinical trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.